한글목차

개요

유아 경련 치료제 시장은 2023-2028년간 8,961만 달러 확대되고, 예측 기간 중 연평균 복합 성장률(CAGR)은 5.41%를 나타낼 것으로 예측됩니다.

유아 경련 치료제 시장에 대한 전체적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 대상으로 한 벤더 분석 등의 정보를 게재했습니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공합니다. 신경학 및 간질 연구의 발전, 소아 경련 및 관련 신경질환 유병률 상승에 따른 유아 경련 치료제 수요 증가, 소아 경련 조기 진단에 대한 의식 고양 등에 의해 시장 성장이 가속되고 있습니다.

본 조사에서는 유전자 치료에 대한 관심 증가가 향후 몇 년간 유아 경련 치료제 시장 성장을 가속하는 주요인 중 하나라고 보고 있습니다. 또한 제약회사, 연구기관, 어드버커시 그룹의 협력에 의한 디지털 헬스 솔루션 통합이나 유아 경련 치료제의 진보 또한 시장의 높은 수요로 연결될 것입니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 생태계

제3장 시장 규모

• 시장의 정의
• 시장 부문 분석
• 시장 규모(2023년)
• 시장 전망(2023-2028년)

제4장 시장 규모 실적

• 세계의 유아 경련 치료제 시장(2018-2022년)
• 투여 경로별 부문 분석(2018-2022년)
• 약물 클래스별 부문 분석(2018-2022년)
• 지역별 부문 분석(2018-2022년)
• 국가별 부문 분석(2018-2022년)

제5장 Five Forces 분석

• Five Forces 요약
• 바이어의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁 위협
• 시장 현황

제6장 시장 세분화 : 투여 경로별

• 시장 부문
• 비교 : 투여 경로별
• 비경구 : 시장 규모와 예측(2023-2028년)
• 경구 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 투여 경로별

제7장 시장 세분화 약제 클래스별

• 시장 부문
• 비교 : 약제 클래스별
• 항경련제 : 시장 규모와 예측(2023-2028년)
• 코르티코스테로이드 : 시장 규모와 예측(2023-2028년)
• 기타 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 약제 클래스별

제8장 고객 상황

• 고객 상황 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측(2023-2028년)
• 유럽 : 시장 규모와 예측(2023-2028년)
• 아시아 : 시장 규모와 예측(2023-2028년)
• 세계 기타 지역 : 시장 규모와 예측(2023-2028년)
• 미국 : 시장 규모와 예측(2023-2028년)
• 독일 : 시장 규모와 예측(2023-2028년)
• 영국 : 시장 규모와 예측(2023-2028년)
• 프랑스 : 시장 규모와 예측(2023-2028년)
• 중국 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 지역 상황별

제10장 성장 촉진요인, 과제 및 동향

• 시장 성장 촉진요인
• 시장이 해결해야 할 과제
• 성장 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란 상황
• 업계 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• Amneal Pharmaceuticals Inc.
• Cipla Ltd.
• Endo International Plc
• H Lundbeck AS
• Hetero Labs Ltd.
• Intas Pharmaceuticals Ltd.
• Jazz Pharmaceuticals Plc
• Mallinckrodt Plc
• Marinus Pharmaceuticals Inc.
• MSN Laboratories
• Ovid Therapeutics Inc.
• Sanofi SA
• SGPharma Pvt. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zydus Lifesciences Ltd.

제13장 부록

영문목차

Abstract

The infantile spasms therapeutics market is forecasted to grow by USD 89.61 mn during 2023-2028, accelerating at a CAGR of 5.41% during the forecast period. The report on the infantile spasms therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advancements in research in neurology and epilepsy, growing demand for infantile spasms therapeutics due to the rising prevalence of infantile spasms and related neurological disorders, and increasing awareness and emphasis on early diagnosis of infantile spasms.

Technavio's infantile spasms therapeutics market is segmented as below:

By Route Of Administration

• Parenteral
• Oral

By Drug Class

• Anticonvulsants
• Corticosteroids
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the growing interest in gene therapy as one of the prime reasons driving the infantile spasms therapeutics market growth during the next few years. Also, increasing integration of digital health solutions and advancements in infantile spasms therapeutics due to collaborations between pharmaceutical companies, research institutions, and advocacy groups will lead to sizable demand in the market.

The report on the infantile spasms therapeutics market covers the following areas:

• Infantile spasms therapeutics market sizing
• Infantile spasms therapeutics market forecast
• Infantile spasms therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading infantile spasms therapeutics market vendors that include Amneal Pharmaceuticals Inc., Cipla Ltd., Endo International Plc, H Lundbeck AS, Hetero Labs Ltd., Intas Pharmaceuticals Ltd., Jazz Pharmaceuticals Plc, Mallinckrodt Plc, Marinus Pharmaceuticals Inc., MSN Laboratories, Ovid Therapeutics Inc., Sanofi SA, SGPharma Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Anavex Life Sciences Corp., Genix Pharma Pvt. Ltd., Jolly Healthcare, and ORPHELIA Pharma. Also, the infantile spasms therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global infantile spasms therapeutics market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global infantile spasms therapeutics market 2018 - 2022 ($ million)
• 4.2 Route of Administration Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
• 4.3 Drug Class Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Route of Administration

• 6.1 Market segments
• Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
• 6.2 Comparison by Route of Administration
• Exhibit 32: Chart on Comparison by Route of Administration
• Exhibit 33: Data Table on Comparison by Route of Administration
• 6.3 Parenteral - Market size and forecast 2023-2028
• Exhibit 34: Chart on Parenteral - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Parenteral - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
• 6.4 Oral - Market size and forecast 2023-2028
• Exhibit 38: Chart on Oral - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Oral - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Oral - Year-over-year growth 2023-2028 (%)
• 6.5 Market opportunity by Route of Administration
• Exhibit 42: Market opportunity by Route of Administration ($ million)
• Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Drug Class

• 7.1 Market segments
• Exhibit 44: Chart on Drug Class - Market share 2023-2028 (%)
• Exhibit 45: Data Table on Drug Class - Market share 2023-2028 (%)
• 7.2 Comparison by Drug Class
• Exhibit 46: Chart on Comparison by Drug Class
• Exhibit 47: Data Table on Comparison by Drug Class
• 7.3 Anticonvulsants - Market size and forecast 2023-2028
• Exhibit 48: Chart on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
• Exhibit 49: Data Table on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
• Exhibit 50: Chart on Anticonvulsants - Year-over-year growth 2023-2028 (%)
• Exhibit 51: Data Table on Anticonvulsants - Year-over-year growth 2023-2028 (%)
• 7.4 Corticosteroids - Market size and forecast 2023-2028
• Exhibit 52: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
• 7.5 Others - Market size and forecast 2023-2028
• Exhibit 56: Chart on Others - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Others - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Others - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by Drug Class
• Exhibit 60: Market opportunity by Drug Class ($ million)
• Exhibit 61: Data Table on Market opportunity by Drug Class ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Germany - Market size and forecast 2023-2028
• Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.9 UK - Market size and forecast 2023-2028
• Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.10 France - Market size and forecast 2023-2028
• Exhibit 95: Chart on France - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on France - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on France - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on France - Year-over-year growth 2023-2028 (%)
• 9.11 China - Market size and forecast 2023-2028
• Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 103: Market opportunity By Geographical Landscape ($ million)
• Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification
• 12.3 Amneal Pharmaceuticals Inc.
• Exhibit 111: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 112: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 113: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 114: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 115: Amneal Pharmaceuticals Inc. - Segment focus
• 12.4 Cipla Ltd.
• Exhibit 116: Cipla Ltd. - Overview
• Exhibit 117: Cipla Ltd. - Business segments
• Exhibit 118: Cipla Ltd. - Key news
• Exhibit 119: Cipla Ltd. - Key offerings
• Exhibit 120: Cipla Ltd. - Segment focus
• 12.5 Endo International Plc
• Exhibit 121: Endo International Plc - Overview
• Exhibit 122: Endo International Plc - Business segments
• Exhibit 123: Endo International Plc - Key news
• Exhibit 124: Endo International Plc - Key offerings
• Exhibit 125: Endo International Plc - Segment focus
• 12.6 H Lundbeck AS
• Exhibit 126: H Lundbeck AS - Overview
• Exhibit 127: H Lundbeck AS - Product / Service
• Exhibit 128: H Lundbeck AS - Key offerings
• 12.7 Hetero Labs Ltd.
• Exhibit 129: Hetero Labs Ltd. - Overview
• Exhibit 130: Hetero Labs Ltd. - Product / Service
• Exhibit 131: Hetero Labs Ltd. - Key offerings
• 12.8 Intas Pharmaceuticals Ltd.
• Exhibit 132: Intas Pharmaceuticals Ltd. - Overview
• Exhibit 133: Intas Pharmaceuticals Ltd. - Product / Service
• Exhibit 134: Intas Pharmaceuticals Ltd. - Key offerings
• 12.9 Jazz Pharmaceuticals Plc
• Exhibit 135: Jazz Pharmaceuticals Plc - Overview
• Exhibit 136: Jazz Pharmaceuticals Plc - Product / Service
• Exhibit 137: Jazz Pharmaceuticals Plc - Key news
• Exhibit 138: Jazz Pharmaceuticals Plc - Key offerings
• 12.10 Mallinckrodt Plc
• Exhibit 139: Mallinckrodt Plc - Overview
• Exhibit 140: Mallinckrodt Plc - Business segments
• Exhibit 141: Mallinckrodt Plc - Key offerings
• Exhibit 142: Mallinckrodt Plc - Segment focus
• 12.11 Marinus Pharmaceuticals Inc.
• Exhibit 143: Marinus Pharmaceuticals Inc. - Overview
• Exhibit 144: Marinus Pharmaceuticals Inc. - Product / Service
• Exhibit 145: Marinus Pharmaceuticals Inc. - Key offerings
• 12.12 MSN Laboratories
• Exhibit 146: MSN Laboratories - Overview
• Exhibit 147: MSN Laboratories - Product / Service
• Exhibit 148: MSN Laboratories - Key offerings
• 12.13 Ovid Therapeutics Inc.
• Exhibit 149: Ovid Therapeutics Inc. - Overview
• Exhibit 150: Ovid Therapeutics Inc. - Product / Service
• Exhibit 151: Ovid Therapeutics Inc. - Key offerings
• 12.14 Sanofi SA
• Exhibit 152: Sanofi SA - Overview
• Exhibit 153: Sanofi SA - Business segments
• Exhibit 154: Sanofi SA - Key news
• Exhibit 155: Sanofi SA - Key offerings
• Exhibit 156: Sanofi SA - Segment focus
• 12.15 SGPharma Pvt. Ltd.
• Exhibit 157: SGPharma Pvt. Ltd. - Overview
• Exhibit 158: SGPharma Pvt. Ltd. - Product / Service
• Exhibit 159: SGPharma Pvt. Ltd. - Key offerings
• 12.16 Teva Pharmaceutical Industries Ltd.
• Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.17 Zydus Lifesciences Ltd.
• Exhibit 165: Zydus Lifesciences Ltd. - Overview
• Exhibit 166: Zydus Lifesciences Ltd. - Business segments
• Exhibit 167: Zydus Lifesciences Ltd. - Key offerings
• Exhibit 168: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 169: Inclusions checklist
• Exhibit 170: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 171: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 172: Research methodology
• Exhibit 173: Validation techniques employed for market sizing
• Exhibit 174: Information sources
• 13.5 List of abbreviations
• Exhibit 175: List of abbreviations